Icon inks Proteome deal to bolster biomarker offering

This content item was originally published on www.biopharma-reporter.com, a William Reed online publication.

By Nick TAYLOR

- Last updated on GMT

Related tags Protein

Icon is adding protein and peptide profiling to its biomarker capabilities through a strategic alliance with Proteome Sciences.

Over the past 10 years Icon has built up its biomarker capabilities as it works to help clients make more informed drug development decisions. Building on this progress Icon has inked a deal with Proteome.

At AAPS 2010 Outsourcing-Pharma discussed the deal with Brian O'Dwyer, vice president (VP) of bioanalytical development, and John Allinson, VP biomarker lab services.

In a press statement Ian Pike, chief operating officer at Proteome, said the deal is recognition of the ‘unique power’ of its proprietary technology platforms.

Related news

Show more

Related products

show more

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers